Casi Pharmaceuticals, Inc. (NASDAQ:CASI)

CAPS Rating: No stars

A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.


Player Avatar ShuntSD (86.27) Submitted: 10/20/2006 2:37:38 PM : Outperform Start Price: $22.55 CASI Score: -154.75

As others say, a gamble with huge upside. But the small molecule research is promising and acquisition was a nice move. Keep close eye on it with stops.

Featured Broker Partners